✦ LIBER ✦

Postmenopausic osteoporosis treatment with yearly doses of intravenous Zoledronic acid. A Venezuelan Observational Study

✍ Scribed by E.J. Nieto; J.R. Salinas; R.A. Torres

Book ID: 116324628
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 85 KB
Volume: 48
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2011.03.506

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Orbital inflammatory disease secondary t

Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis

✍ F. Procianoy; E. Procianoy 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 124 KB

Efficacy and Safety of a Once-Yearly Int

Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older

✍ Steven Boonen; Dennis M. Black; Cathleen S. Colón-Emeric; Richard Eastell; Jay S 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB

Bone material properties in actively bon

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci

The effect of intravenous zolendronic ac

The effect of intravenous zolendronic acid (ZOL) 5mgs once yearly in the treatment of postmenopausal osteoporosis. A peripheral quantitative computed tomography (PQCT) study

✍ K. Stathopoulos; P. Katsimbri; E. Metania; E. Atsali; E. Eustathopoulos; A.B. Zo 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 71 KB

A community-based clinical trial of Intr

A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial: Methodological considerations

✍ Jacques P. Brown; J.D. Adachi; D.L. Kendler; R. Rigal; G. Deutsch; J.M. Leclerc 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi